Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
Tóm tắt
Purpose: Previous research identified differences in breast cancer–specific mortality across 4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 positive/estrogen receptor negative (HER2+/ER−).
Experimental Design: We used immunohistochemical markers to subtype 1,149 invasive breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a population-based study of women diagnosed with breast cancer. Vital status was determined through 2006 using the National Death Index, with median follow-up of 9 years.
Results: Cancer subtypes luminal A, luminal B, basal-like, and HER2+/ER− were distributed as 64%, 11%, 11%, and 5% for whites, and 48%, 8%, 22%, and 7% for African Americans, respectively. Breast cancer mortality was higher for participants with HER2+/ER− and basal-like breast cancer compared with luminal A and B. African Americans had higher breast cancer–specific mortality than whites, but the effect of race was statistically significant only among women with luminal A breast cancer. However, when compared with the luminal A subtype within racial categories, mortality for participants with basal-like breast cancer was higher among whites (HR = 2.0, 95% CI: 1.2–3.4) than African Americans (HR = 1.5, 95% CI: 1.0–2.4), with the strongest effect seen in postmenopausal white women (HR = 3.9, 95% CI: 1.5–10.0).
Conclusions: Our results confirm the association of basal-like breast cancer with poor prognosis and suggest that basal-like breast cancer is not an inherently more aggressive disease in African American women compared with whites. Additional analyses are needed in populations with known treatment profiles to understand the role of tumor subtypes and race in breast cancer mortality, and in particular our finding that among women with luminal A breast cancer, African Americans have higher mortality than whites. Clin Cancer Res; 16(24); 6100–10. ©2010 AACR.
Từ khóa
Tài liệu tham khảo
Seer.cancer.gov [Internet]
Carey, 2006, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 295, 2492, 10.1001/jama.295.21.2492
Lund, 2009, Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA, Breast Cancer Res Treat, 113, 357, 10.1007/s10549-008-9926-3
Cheang, 2008, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 14, 1368, 10.1158/1078-0432.CCR-07-1658
Yang, 2007, Differences in risk factors for breast cancer molecular subtypes in a population-based study, Cancer Epidemiol Biomarkers Prev, 16, 439, 10.1158/1055-9965.EPI-06-0806
Kim, 2006, Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes, Human Pathol, 37, 1217, 10.1016/j.humpath.2006.04.015
Kurebayashi, 2007, The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races, Breast, 16, S72, 10.1016/j.breast.2007.07.017
Lin, 2009, Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia, Cancer Epidemiol Biomarkers Prev, 18, 1807, 10.1158/1055-9965.EPI-09-0096
Millikan, 2007, Epidemiology of basal-like breast cancer, Breast Cancer Res Treat, 109, 123, 10.1007/s10549-007-9632-6
Ihemelandu, 2008, Treatment and survival outcome for molecular breast cancer subtypes in black women, Ann Surg, 247, 463, 10.1097/SLA.0b013e31815d744a
Nalwoga, 2007, Frequency of the basal-like phenotype in African breast cancer, APMIS, 115, 1391, 10.1111/j.1600-0463.2007.00862.x
Huo, 2009, Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer, J Clin Oncol, 27, 4515, 10.1200/JCO.2008.19.6873
Sihto, 2008, Molecular subtypes of breast cancers detected in mammography screening and outside of screening, Clin Cancer Res, 14, 4103, 10.1158/1078-0432.CCR-07-5003
Foulkes, 2009, Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status, Breast Cancer Res Treat, 117, 199, 10.1007/s10549-008-0102-6
Shin, 2008, Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status, Oncol Rep, 19, 617
Nakajima, 2008, Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining, World J Surg, 32, 2477, 10.1007/s00268-008-9712-8
Spitale, 2009, Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland, Ann Oncol, 20, 628, 10.1093/annonc/mdn675
Zhao, 2009, Characteristics and prognosis for molecular breast cancer subtypes in Chinese women, J Surg Oncol, 100, 89, 10.1002/jso.21307
Onitilo, 2009, Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival, Clin Med Res, 7, 4, 10.3121/cmr.2008.825
Parise, 2009, Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004, Breast J, 15, 593, 10.1111/j.1524-4741.2009.00822.x
Muñoz, 2009, Prognostic significance of molecular classification of breast invasive ductal carcinoma, Arch of Gynecol and Obstet, 280, 43, 10.1007/s00404-008-0867-1
Liu, 2008, Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers, Hum Pathol, 39, 167, 10.1016/j.humpath.2007.06.012
Yamamoto, 2009, Clinical significance of basal-like subtype in triple-negative breast cancer, Breast Cancer, 16, 260, 10.1007/s12282-009-0150-8
Ibrahim, 2009, Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor and HER-2 as surrogate markers, Med Oncol, 26, 372, 10.1007/s12032-008-9131-6
Gray, 1992, Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis, J Am Stat Assoc, 87, 942, 10.1080/01621459.1992.10476248
Natarajan, 2009, Time-varying effects of prognostic factors associated with disease-free survival in breast cancer, Am J Epidemiol, 169, 1463, 10.1093/aje/kwp077
Newman, 1995, The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology, Breast Cancer Res Treat, 35, 51, 10.1007/BF00694745
Sørlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA, 98, 10869, 10.1073/pnas.191367098
Rich-Edwards, 1994, Test of the National Death Index and Equifax nationwide death search, Am J Epidemiol, 140, 1016, 10.1093/oxfordjournals.aje.a117191
Greenland, 1999, Causal diagrams for epidemiologic research, Epidemiology, 10, 37, 10.1097/00001648-199901000-00008
Cole, 2002, Fallibility in estimating direct effects, Int J Epidemiol, 31, 163, 10.1093/ije/31.1.163
Harrell, 2001, Regression Modeling Strategies, with Applications to Linear Models, Logistic Regression, and Survival Analysis
Komenaka, 2010, Race and ethnicity and breast cancer outcomes in an underinsured population, J Natl Cancer Inst, 102, 1178, 10.1093/jnci/djq215
Dent, 2009, Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status, Cancer, 115, 4917, 10.1002/cncr.24573
Dent, 2007, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, 13, 4429, 10.1158/1078-0432.CCR-06-3045
Tischkowitz, 2007, Use of immunohistochemical markers can refine prognosis in triple negative breast cancer, BMC Cancer, 7, 134, 10.1186/1471-2407-7-134
Anderson, 2006, Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002), Breast Cancer Res Treat, 99, 333, 10.1007/s10549-006-9214-z
Gore, 1984, Regression models and non-proportional hazards in the analysis of breast cancer survival, App Stat, 33, 176, 10.2307/2347444
Huang, 2000, Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status, Am J Epidemiol, 151, 703, 10.1093/oxfordjournals.aje.a010265
Ma, 2009, Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports, Cancer Epidemiol Biomarkers Prev, 18, 2214, 10.1158/1055-9965.EPI-09-0301
Fillenbaum, 2009, Identifying a national death index match, Am J Epidemiol, 170, 515, 10.1093/aje/kwp155
Sathiakumar, 1998, Using the National Death Index to obtain underlying cause of death codes, J Occup and Environ Med, 40, 808, 10.1097/00043764-199809000-00010
Huang, 2010 4, Population-based survival-curve analysis of ER-negative breast cancer, Breast Cancer Res Treat, 10.1007/s10549-010-0752-z